

Appl. No. : 10/087,013
Filed : February 21, 2002

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-11, 13-20, and 22-55 without prejudice, amend Claims 12 and 21, and add Claims 56-61 as follows:

1-11 (Canceled)

12. (Currently Amended) A purified or isolated protein comprising the sequence of SEQ ID NO:2 ~~SEQ ID NO:2~~.

13-20 (Canceled)

21 (Currently Amended) A purified or isolated polypeptide comprising a DBL3 or ~~CIDR1~~ domain of residues 1279-1554 of SEQ ID NO:2 or immunogenic fragment thereof consisting of at least 15 or 30 ~~9~~ amino acids of residues 1279-1554 of SEQ ID NO:2 ~~SEQ ID No:2~~.

22-55 (Canceled)

56 (New) The purified or isolated polypeptide of Claim 21, wherein the polypeptide is the DBL3 domain of residues 1279-1554 of SEQ ID NO:2.

57. (New) The purified or isolated polypeptide of Claim 21, wherein the polypeptide is the immunogenic fragment consisting of at least 15 amino acids of residues 1279-1554 of SEQ ID NO:2.

58. (New) The purified or isolated polypeptide of Claim 21, wherein the polypeptide is the immunogenic fragment consisting of at least 30 amino acids of residues 1279-1554 of SEQ ID NO:2.

59. (New) An immunogenic composition comprising the protein or polypeptide of any of Claims 12, 56, 57, or 58 in combination with a pharmaceutically acceptable carrier or adjuvant.

60. (New) A method of inducing an immune response comprising administering the composition of Claim 59 to a subject in need thereof, wherein an immune response is induced.

61. (New) The method of Claim 60 wherein the subject is at risk for maternal malaria.